

Trust Headquarters
 Russell's Hall Hospital
 Dudley
 West Midlands
 DY1 2HQ

Ref: FOI-102024-0001198

Date: 19/11/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

1. How many **newly diagnosed** patients with chronic lymphocytic leukaemia (CLL) have **started first-line treatment** in your Trust or Centre during the 6-month period February 2024 to July 2024?

Answer:

2. How many of these **newly diagnosed** patients with CLL **received chemoimmunotherapy (CIT) as first-line treatment?**

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

Answer:

3. Please complete the table below with how many **newly diagnosed** patients with CLL have **started first-line treatment** with each of the following CITs during the 6-month period February 2024 to July 2024
 - FCR (fludarabine + cyclophosphamide + rituximab)
 - FR (fludarabine + rituximab)
 - BR (bendamustine + rituximab)
 - Bendamustine monotherapy
 - RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
 - Obinutuzumab ± chlorambucil
 - Rituximab + chlorambucil
 - Ofatumumab
 - Other – please specify

Note: this should only include **newly diagnosed** patients with CLL who have **started first-line treatment during the 6-month window**

Answer:

Treatment option	Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024
FCR	
FR	

BR	
Bendamustine monotherapy	
R-CHOP	
Obinutuzumab ± chlorambucil	
Rituximab + chlorambucil	
Chlorambucil monotherapy	
Rituximab monotherapy	
Ofatumumab	
Other – please specify	

Response

Q1. < 5

Q2. < 5

Q3. > 5

Please note that as per NHS Digital rules the Trust does not publish numbers lower than 5 as this could lead to the identification of the persons involved and cause distress to Families or Friends. The requested information over the timeframe requested is less than 5, therefore, Exemption Section 40(2) of the Freedom of Information Act is applied

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dqft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team
The Dudley Group NHS Foundation Trust**